Dermatology

These pivotal phase 3 data on povorcitinib were the results of the STOP-HS clinical trial, with results suggesting both efficacy and safety for hidradenitis suppurativa.

This quiz, the fourth in this series, assesses your knowledge in post-AK treatment surveillance strategies, risk stratification, and more.

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

This interview with Yamauchi highlights phase 3b findings on tildrakizumab among patients with moderate-to-severe nail psoriasis.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

Carolyn Goh, MD, spoke in this AAD 2025 interview about her talk on guidance in addressing patients with hair disorders.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

Andrew Alexis, MD, MPH, highlights his ‘What’s New’ talk at AAD 2025 on new practices for treating pigmentary disorders such as vitiligo.

This interview with Andrew Alexis, MD, MPH, features some of the most notable highlights from his AAD 2025 talks on therapeutic and diagnostic pearls for skin of color.

Bernstein also discussed other unmet needs in the field and how his center is working to address them.

In this interview with Christopher Bunick, MD, PhD, at AAD 2025, he discusses his update given in a presentation regarding acne and rosacea treatments.

This interview features a discussion with Christopher Bunick, MD, PhD, regarding recent controversies in acne and rosacea related to benzene and benzoyl peroxide.

These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.

This AAD 2025 interview with Bhutani covers some of the takeaways from her presentation on use of JAK inhibitors for alopecia areata among pregnant or breastfeeding women.

In this interview at AAD 2025, Bhutani highlights several points of consideration for clinicians treating patients who are pregnant and suffering from alopecia areata.

This interview with Melinda Gooderham, MD, covers recent findings from the phase 3 ARRECTOR trial on roflumilast foam 0.3% in scalp and body psoriasis.

This interview at the Skin of Color Society (SOCS) Scientific Symposium features Elbuluk describing her plans as newly-elected president of SOCS.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Crystal Aguh, MD, discusses a study from AAD 2025 examining HbA1c levels and outcomes in CCCA.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

This interview with Snyder features a discussion on recent findings on remibrutinib among patients with chronic spontaneous urticaria, also known as CSU.